Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia

Leukemia

Volumn 28, Issue 7, 2014, Pages 1543-1545

  Ravandi, F ^a   Arana Yi, C ^a   Cortes, J E ^a   Levis, M ^b   Faderl, S ^a   Garcia Manero, G ^a   Jabbour, E ^a   Konopleva, M ^a   O'Brien, S ^a   Estrov, Z ^a   Borthakur, G ^a   Thomas, D ^a   Pierce, S ^a   Brandt, M ^a   Pratz, K ^b   Luthra, R ^a   Andreeff, M ^a   Kantarjian, H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; CREATININE; CYTARABINE; IDARUBICIN; SORAFENIB;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANOREXIA; BLEEDING; COLITIS; DIARRHEA; DISEASE FREE SURVIVAL; EVENT FREE SURVIVAL; GENE MUTATION; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; INFECTION; LETTER; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; OVERALL SURVIVAL; PANCREATITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SALVAGE THERAPY; SIDE EFFECT; WEIGHT GAIN;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; HUMANS; IDARUBICIN; LEUKEMIA, MYELOID, ACUTE; NIACINAMIDE; PHENYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 84904043013     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.54     Document Type: Letter

References (12)

1. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004 64 7099-7109.
2. Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X et al. Mutant FLT3 a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 2008 100 184-198.
3. Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010 28 1856-1862.
4. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001 98 1752-1759.
5. Santos FP, Jones D, Qiao W, Cortes JE, Ravandi F, Estey EE et al. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. Cancer 2011 117 2145-2155.
6. Fischer T, Stone RM, Deangelo DJ, Galinsky I, Estey E, Lanza C et al. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and highrisk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 2010 28 4339-4345.
7. Fiedler W, Serve H, Dohner H, Schwittay M, Ottmann OG, O'Farrell AM et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005 105 986-993.
8. Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 2011 117 3294-3301.
9. Yee KW, Schittenhelm M, O'Farrell AM, Town AR, McGreevey L, Bainbridge T et al. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITDpositive leukemic cells. Blood 2004 104 4202-4209.
10. Man CH, Fung TK, Ho C, Han HH, Chow HC, Ma AC et al. Sorafenib treatment of FLT3-ITD(\+) acute myeloid leukemia favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. Blood 2012 119 5133-5143.
11. Serve H, Krug U, Wagner R, Sauerland MC, Heinecke A, Brunnberg U et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia results from a randomized, placebo-controlled trial. J Clin Oncol 2013 31 3110-3118.
12. Rollig C, Müller-Tidow C, Hü ttmann A, Kunzmann V, Baldus CD, Brandts CH et al. Sorafenib versus placebo in addition to standard therapy in adult patients r60 years with newly diagnosed acute myeloid leukemia results from the randomized-controlled soraml trial. Blood 2012 120 Abstract 144.